UK Government Laments Tamiflu Secrets

A parliamentary committee says drugmakers have not disclosed enough data on the anti-influenza medicine.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, CATHERINEDespite the UK government stockpiling £424 million ($694.3 million) worth of the antiviral medication Tamiflu, doctors and researchers are unable tp make informed decisions about its use because of a lack of public data on the drug's safety and efficacy, according to the Public Accounts Committee of Parliament.

Committee member Richard Bacon, who is a member of parliament, told the BBC: “The full results of clinical trials are being routinely and legally withheld from doctors and researchers by the manufacturers of medicines.” On top of that, the committee had “extreme concern” that positive trial results were more likely to be published than negative ones, Bacon said.

Members of a Cochrane Collaboration group tasked with analyzing clinical trial results of Tamiflu have long complained that Roche, which markets the drug, has withheld considerable data from public scrutiny. The parliamentary committee now agrees. Bacon told The Guardian that “the lack of transparency of clinical trial information on this drug to the wider research community is preventing proper discussion of this issue among professionals. We are ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies